Search Within

Diana E Lake

Formats
  1. Meeting Abstract (48)
  2. Journal Article (39)
  3. Book Whole (1)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (89)
  2. Department of Medicine (89)
  3. Solid Tumor Oncology Division (89)
  4. Survivorship Research (89)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (55)
  6. Epidemiology and Biostatistics (48)

More Groups

People
  1. Clifford Hudis (65)
  2. Larry Norton (45)
  3. Gabriella D'Andrea-Carlino (39)
  4. Chau Dang (37)
  5. Monica Fornier (36)
  6. Maura Dickler (33)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (1)
  4. 2022 (4)
  5. 2021 (1)
  6. 2020 (2)

More Years

Publications
  1. Journal of Clinical Oncology (30)
  2. Cancer Research (16)
  3. Breast Cancer Research and Treatment (13)
  4. Clinical Breast Cancer (7)
  5. Clinical Cancer Research (4)
  6. Annals of Oncology (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (20)
  3. Springer (14)
  4. Elsevier Inc. (9)
  5. Oxford University Press (3)
  6. American Medical Association (2)

More Publishers

Results (89)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance)
    Journal Article

    Dickler, M. N.; Barry, W. T.; Cirrincione, C. T.; Ellis, M. J.; Moynahan, M. E.; Innocenti, F.; Hurria, A.; Rugo, H. S.; Lake, D. E.; Hahn, O.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance)
    Meeting Abstract

    Dickler, M. N.; Barry, W. T.; Cirrincione, C. T.; Ellis, M. J.; Moynahan, M. E.; Innocenti, F.; Hurria, A.; Rugo, H. S.; Lake, D.; Hahn, O. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?
    Journal Article

    Jochelson, M. S.; Lampen Sachar, K.; Gibbons, G.; Dang, C.; Lake, D.; Morris, E. A.; Morrow, M.
    Annals of Surgical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
    Meeting Abstract

    Gajria, D.; Modi, S.; Saura, C.; Sakr, R.; Solano, K.; Won, H.; Pannu, H.; Patil, S.; Lake, D.; Traina, T.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save